NEW YORK (GenomeWeb) – Qiagen said this week that a judge has recommended partial dismissal of lawsuit filed against the company by Oxford Immunotec for patent infringement. The suit, filed in August 2015, concerns six patents and Qiagen's QuantiFERON Gold latent TB test. Oxford Immunotec alleged that Qiagen and other companies had infringed on its patents by developing their own TB tests. A magistrate judge has now recommended that part of the case against the defendants be dismissed as part of Oxford Immunotec's patents covered unpatentable subject matter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.